Granulysin as a Marker for Early Diagnosis of the Stevens–Johnson Syndrome

Letters6 October 2009Granulysin as a Marker for Early Diagnosis of the Stevens–Johnson SyndromeRiichiro Abe, MD, PhD, Naoya Yoshioka, MS, Junko Murata, MD, Yasuyuki Fujita, MD, and Hiroshi Shimizu, MD, PhDRiichiro Abe, MD, PhDFrom Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan., Naoya Yoshioka, MSFrom Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan., Junko Murata, MDFrom Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan., Yasuyuki Fujita, MDFrom Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan., and Hiroshi Shimizu, MD, PhDFrom Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-7-200910060-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening adverse drug reactions characterized by massive epidermal necrosis. In the early stage, clinical presentations of SJS/TEN are very similar to those of ordinary drug-induced skin reactions (ODSRs); therefore, SJS/TEN is difficult to diagnose and the start of treatment is often delayed, resulting in high mortality rates. Other investigators (1) reported that granulysin is highly expressed in blisters of SJS/TEN and causes disseminated keratinocyte death. Because SJS/TEN progresses and spreads rapidly, the granulysin level should be increased in the serum of patients with active SJS/TEN if it is a ...References1. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343-50. [PMID: 19029983] CrossrefMedlineGoogle Scholar2. Ogawa K, Takamori Y, Suzuki K, Nagasawa M, Takano S, Kasahara Y, et al. Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol. 2003;33:1925-33. [PMID: 12884856] CrossrefMedlineGoogle Scholar3. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122:992-1000. [PMID: 18692887] CrossrefMedlineGoogle Scholar4. Kaspar AA, Okada S, Kumar J, Poulain FR, Drouvalakis KA, Kelekar A, et al. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol. 2001;167:350-6. [PMID: 11418670] CrossrefMedlineGoogle Scholar5. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-20. [PMID: 12707034] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Riichiro Abe, MD, PhD; Naoya Yoshioka, MS; Junko Murata, MD; Yasuyuki Fujita, MD; Hiroshi Shimizu, MD, PhDAffiliations: From Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDelayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune MediatorsToxic Epidermal Necrolysis: A Case Report on a Drug-Induced PhenomenonA Review of the Systemic Treatment of Stevens–Johnson Syndrome and Toxic Epidermal NecrolysisAdvances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug ReactionsAdvances in the Pathomechanisms of Delayed Drug HypersensitivityStevens-Johnson Syndrome and Toxic Epidermal NecrolysisStevens–Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems MedicineMechanisms of Drug HypersensitivityDeep Neural Network for Early Image Diagnosis of Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisSystemic Corticosteroid Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Vietnam: Clinical Evaluation and Analysis of Serum CytokinesStevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and ManagementTRIMETHOPRIM-SULFAMETHOXAZOLE AND SODIUM VALPROATE-INDUCED TOXIC EPIDERMAL NECROLYSIS: A CASE SERIESDiagnostic Tools and Biomarkers for Severe Drug EruptionsCurrent Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisDrug toxicoderma: possible causes, clinical manifestations and approaches to management at the outpatient's stageDetecting Lesional Granulysin Levels for Rapid Diagnosis of Cytotoxic T lymphocyte–Mediated Bullous Skin DisordersThe Roles of Immunoregulatory Networks in Severe Drug HypersensitivityDiagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysisRIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysisKnocking 'em Dead: Pore-Forming Proteins in Immune DefenseStevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategiesWound Management in Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisRecent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysisMutant GNLY is linked to Stevens–Johnson syndrome and toxic epidermal necrolysisGalectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cellsSpectrum of gastrointestinal involvement in Stevens - Johnson syndromeImmunology of Cutaneous Adverse Drug ReactionsDiagnosis of main rashes in childrenPathology of Mucocutaneous Diseases with Lichenoid Tissue Reaction/Interface Dermatitis Characterized by Keratinocyte DeathDrug-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via PharmacogenomicsAdverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex ReactionsVancomycin-Induced Stevens-Johnson Syndrome in a Boy Under 2 Years Old: An Early Diagnosis by Granulysin Rapid TestCurrent Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisDiagnosing and managing patients with drug hypersensitivityDelayed‐type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T‐cell reactivity studyAn Updated Review of the Molecular Mechanisms in Drug HypersensitivityVariable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysisToxic Epidermal Necrolysis, Problems of Diagnosis and TherapyInterleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisToxic Epidermal Necrolysis - A Case ReportMultifactorial Diseases with Immunological InvolvementDrug induced exfoliative dermatitis: state of the artSuccessful Combination Therapy Including Plasma Exchange for Severe Toxic Epidermal NecrolysisHistopathology of the Exanthema in DRESS Is Not Specific but May Indicate Severity of Systemic InvolvementCutaneous Adverse Drug Reactions: Stevens–Johnson Syndrome and Toxic Epidermal NecrolysisA Review of the Pathogenesis of Toxic Epidermal NecrolysisInsights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinIn vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiologySerum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsClinical perspectives and murine models of lichenoid tissue reaction/interface dermatitisTowards the development of mechanism-based biomarkers to diagnose drug hypersensitivityPurpura Fulminans in Toxic Epidermal NecrolysisImmunological response in Stevens-Johnson syndrome and toxic epidermal necrolysisStevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): Could Retinoids Play a Causative Role?Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative reviewThe study of severe cutaneous drug hypersensitivity reactions from a systems biology perspectiveAn annexin A1–FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactionsA case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazoleGeneralized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological featuresSerum granulysin as a possible key marker of the activity of alopecia areataMesenteric Ischemia Secondary to Toxic Epidermal NecrolysisUpdate on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysisToxic epidermal necrolysisToxic epidermal necrolysisToxic epidermal necrolysisStevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patientsDistinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologicallyImmunological mechanisms of epidermal damage in toxic epidermal necrolysisProlonged elevation of serum granulysin in drug-induced hypersensitivity syndrome15 kDa Granulysin Causes Differentiation of Monocytes to Dendritic Cells but Lacks Cytotoxic ActivityRecent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosisTratamiento de necrólisis epidérmica tóxica con ciclosporina AThe innate immune system in delayed cutaneous allergic reactions to medicationsRapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysisToxic epidermal necrolysis and Stevens-Johnson syndrome: A review*Drug eruptions in dermatologyIn vitro diagnosis of T cell-mediated drug allergyToxic epidermal necrolysis and Stevens-Johnson syndromeImmunological aspects of nonimmediate reactions to β-lactam antibiotics 6 October 2009Volume 151, Issue 7Page: 514-515KeywordsAdverse reactionsBlistersCellsDrugsHealth statisticsKeratinocytesLesionsNecrosisSkin reactionUlcers ePublished: 6 October 2009 Issue Published: 6 October 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...